Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Ocular Therapeutix Inc Rose 25.6% Today

By Maxx Chatsko - Jul 11, 2017 at 3:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma thinks it just fixed its problems with the FDA.

What happened

Tiny biopharma Ocular Therapeutix (OCUL -6.02%) rose as much as 26% today after announcing that it had submitted an amendment to its existing New Drug Application, or NDA, for lead drug candidate Dextenza. The amendment contains information regarding manufacturing equipment changes and follows feedback provided by the U.S. Food and Drug Administration (FDA) after site inspections conducted earlier this year.

This move was expected by investors, and is the first step needed to begin heading in the right direction -- and toward potential marketing approval for Dextenza -- following several regulatory setbacks. As of 2:55 p.m. EDT, the stock had settled to a 17.6% gain.

A graphic representing stock growth.

Image source: Getty Images.

So what

Ocular Therapeutix has completed three phase 3 trials for Dextenza, a small medical device that's inserted into the small opening of the eyelid following eye surgery. It releases a full dose of postoperative steroid therapy to treat pain and inflammation for 30 days before dissolving. The company submitted an NDA in February 2017, which was accepted by the FDA, for inserting the device and treating postoperative pain. That set a regulatory decision date of July 19, 2017.

However, following reinspection of manufacturing facilities, the FDA issued a Form 483 to the biopharma in May 2017. It discovered certain manufacturing processes were acting as sources of contamination for Dextenza, specifically introducing particulate into the formulation. The presence of foreign materials and contamination is obviously unacceptable for a drug that will be released onto the surface of a patient's eye.

That brings investors to today. Ocular Therapeutix responded to each issue raised in the Form 483 and submitted an amendment to the NDA from February. Not only that, it requested that the FDA extend the review date for an additional three months, since July 19 would not allow enough time to review the new information. If accepted, it's a big win for the company and investors.

Now what

Investors simply have to wait for the FDA's response to the company's request. There are no guarantees that the manufacturing changes from Ocular Therapeutix will bring operations back into compliance, but problems with particulate contamination have arisen many times before in the industry.

Once the proper sources of contamination are identified, it's relatively simple to address with the proper protocols. Although investors have to wait, this is a good sign for potentially gaining marketing approval for Dextenza -- and finally generating meaningful revenue.

Maxx Chatsko has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocular Therapeutix, Inc. Stock Quote
Ocular Therapeutix, Inc.
$5.46 (-6.02%) $0.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.